Inspira Technologies Oxy Bhn Ltd Stock Price, News & Analysis

Inspira Technologies (Nasdaq: IINN) announced its participation in the iECOs Conference happening on November 10, 2022, in Tel Aviv, Israel. The company's CTO, Daniella Yeheskely-Hayon, Ph.D., will deliver a guest lecture during the Physiology and Technology session, showcasing Inspira's innovative respiratory support technology. This technology aims to enhance patient oxygen saturation levels while minimizing the need for invasive procedures. Additionally, the scientific team will be available at their booth to provide insights and answer questions about their ongoing product developments.

Inspira Technologies (NASDAQ:IINN, IINNW) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on October 22, 2022, at 7 p.m. ET. During the interview, President Joe Hayon will discuss the Company's InspiraART System and HYLA blood sensor, highlighting significant market opportunities and their product pipeline. The InspiraART technology aims to improve patient oxygen saturation while reducing reliance on invasive mechanical ventilation. The technology is yet to be tested in humans and is pending regulatory approval.

On September 7, 2022, Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announced the completion of an animal study for its HYLA™ blood sensor at Lahav C.R.O. The sensor, which is non-invasive, offers real-time measurements of blood parameters, potentially improving patient monitoring and reducing risks compared to standard blood gas analyzers. The successful animal study follows earlier laboratory data and marks a significant step toward initiating human studies. This advancement is integral to Inspira's innovative respiratory support technology aimed at enhancing patient care.

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced that President Joe Hayon will present at the H.C. Wainwright 24th Annual Global Investor Conference on September 12, 2022, at 7:00 a.m. ET. One-on-one meetings with Hayon will take place on September 13-14, 2022. Inspira Technologies is known for its innovative Augmented Respiration Technology, aimed at improving patient oxygen saturation without invasive procedures. The technology is not yet approved for human use. For further details, visit their Investor Relations page.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) reported its Q2 2022 financial results, highlighting a net loss of $3.5 million, down from $8.2 million a year earlier. Cash reserves stood at $19.2 million as of June 30, 2022. The company's R&D expenses rose to $2.7 million, driven by increased projects and share-based compensation. Inspira introduced the HYLA™ non-invasive blood sensor and revealed the ALICE™ Device for cardiopulmonary bypass, targeting respective markets of $2.5 billion and significant deployment agreements in Israel and the U.S.

Inspira Technologies has introduced the Liby™ System, a next-generation extracorporeal membrane oxygenation (ECMO) device aimed at the $531 million global ECMO market. The company plans to submit for FDA approval in the first half of 2023, anticipating a Class II 510(k) designation that may not require human trials. The Liby™ system features innovative capabilities such as continuous patient monitoring integration with HYLA™ technology, reducing medical care costs through a consumable sales model.

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has unveiled the Liby™ System, a new extracorporeal membrane oxygenation (ECMO) device designed to treat severe heart and lung failure. Targeting a $531 million global ECMO market, the system is set for FDA submission in H1 2023 and may qualify as a Class II 510(k) device, potentially bypassing human trials. The Liby™ system aims to enhance patient mobility and usability in ICUs, generating recurring revenue through disposable kits, similar to its ART™ system.

Inspira Technologies has signed a strategic agreement with Glo-Med Networks for the potential distribution of the HYLA™ Blood Sensors across six US states over three years, pending regulatory approvals. This contract includes a minimum purchase commitment of 3,889 sensors and 264,873 disposable units, potentially worth $59 million. This agreement follows a previous contract for the ART™ system and positions Inspira for significant growth in the medical device market.

Inspira Technologies (NASDAQ: IINN) announced the development of the non-invasive HYLA™ blood sensor, aiming to transform patient monitoring by providing continuous, real-time blood analysis without drawing blood. Targeting a potential $2.5 billion market, the sensor's applications include critical care settings and various medical procedures. Designed using machine learning, it can measure key health indicators like oxygen and carbon dioxide levels. The technology is still in development and requires regulatory approval.